GDNF treatment in Parkinson's disease: Time for controlled clinical trials?

Brain

Volumn 125, Issue 10, 2002, Pages 2149-2151

  Brundin, Patrik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APPETITE DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; MENTAL DISEASE; MONKEY; NAUSEA; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVE SPROUTING; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RAT; SENSORY DYSFUNCTION; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 0036788442     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awf217     Document Type: Editorial

References (20)

1. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. [Review]. Nat Rev Neurosci 2002; 3: 383-94.
2. Armstrong RJ, Barker RA. Neurodegeneration: a failure of neuroregeneration? Lancet 2001; 358: 1174-6.
3. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002; Aug 5 [epub ahead of print].
4. Björklund A, Rosenblad C, Winkler C, Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. [Review]. Neurobiol Dis 1997; 4: 186-200.
5. Björklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. [Review]. Brain Res 2000; 886: 82-98.
6. Fallon J, Reid S, Kinyami R, Opole I, Opole R, Baratta J, et al. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci USA 2000; 97: 14686-91.
7. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380: 252-5.
8. Gill SS, Patel NK, O'Sullivan K, Brooks DJ, Hotton GR, Svendsen CN, et al. Intraparenchymal putaminal administration of glial- derived neurotrophic factor in the treatment of advanced Parkinson's disease. Neurology 2000; 58 (Suppl 3): A241.
9. Grondin R, Zhang Z, Yi A, Cass WA, Masswood N, Andersen AH, et al. Striatal GDNF infusion promotes structral and functional recovery in advanced parkinsonian monkeys. Brain 2002; 125: 2190-2200.
10. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46: 419-24.
11. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290: 767-73.
12. Lie DC, Dziewczapolski G, Willhoite AR, Kaspar BK, Shults CW, Gage FH. The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci 2002; 22: 6639-49.
13. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-2.
14. Magavi SS, Leavitt BR, Macklis JD. Induction of neurogenesis in the neocortex of adult mice. Nature 2000; 405: 951-5.
15. Nakatomi H, Kuriu T, Okabe S, Yamamato S, Hatano O, Kawahara N, et al. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell 2002; 110: 429-41.
16. Pencea V, Bingaman KD, Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 2001; 21: 6706-17.
17. Robinson R. Experimental transplant treatments for Parkinson's disease. Neurol Rev 2002; 10: 8-11.
18. Temple S. Stem cell plasticity-building the brain of our dreams. [Review]. Nat Rev Neurosci 2001; 2: 513-20.
19. Zhao Z, Momma S, Delfani K, Johansson CB, Frisén J, Janson AM. Neurogenesis in the adult mammalian substantia nigra [abstract]. Soc Neurosci Abstr 2001; 895.1
20. Zurn AD, Widmer HR, Aebischer P. Sustained delivery of GDNF: towards a treatment for Parkinson's disease. [Review]. Brain Res Brain Res Rev 2001; 36: 222-9.